4D-125 IVT not checked

4D Molecular Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.”In the company’s words, NCT04517149 on ClinicalTrials.gov
Tested for
X-Linked Retinitis Pigmentosa
Main trialPhase 1/2
“This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).”In the company’s words, NCT04517149 on ClinicalTrials.gov

Other drugs for X-Linked Retinitis Pigmentosa

All 79 drugs for X-Linked Retinitis Pigmentosa

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Jun 2026 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow 4D-125 IVT

Following is part of Solo: you see every change to 4D-125 IVT the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in